Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese journal of integrative medicine ; (12): 795-800, 2016.
Artigo em Inglês | WPRIM | ID: wpr-301065

RESUMO

Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM), particularly CM served as blood activating and stasis resolving (BASR, Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However, recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that (1) BASR-CM might emphasize on a balanced multi-cytokines network interaction; (2) BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; (3) BASR-CM might mainly act on perivascular cells, either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases, or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.


Assuntos
Animais , Humanos , Inibidores da Angiogênese , Química , Usos Terapêuticos , Antineoplásicos , Usos Terapêuticos , Medicamentos de Ervas Chinesas , Química , Usos Terapêuticos , Modelos Biológicos , Neovascularização Patológica , Sangue , Tratamento Farmacológico
2.
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care ; (6)2006.
Artigo em Chinês | WPRIM | ID: wpr-529444

RESUMO

Objective: To observe blood-activating and stasis-resolving therapy (活血化瘀法)for patients with acute hypertensive cerebral hemorrhage small and moderate in amount and its influence on patients daily ability. Methods: One hundred and twenty-four cases were randomly divided into 3 groups: A group (n=52 cases), B group (n=34) and C group (n=38). Besides conventional therapies, A and B groups were treated additionally with 20 ml of Danshen injection (丹参注射液) in 5% glucose solution 250 ml for intravenous drip (once a day), 28 days constituting one therapeutic course, the beginning of the injection in A group was 24-48 hours after the attack and that of B group, 1 week after the attack. All the cases were evaluated by effective rate, neural defect score (NDS), ability of daily life (ADL), modified Barthel index (MBI), the duration for the absorption of intracranial hematoma, mortality, etc. The therapeutic effects of the 3 groups were compared after the treatment for 28 days, 3 months and 6 months. Results: The total significant effective rates in A group and B group were significantly better than that of C group (all P0.05). Conclusion: The early use of blood-activating and stasis-resolving therapy is effective for patients with acute hypertensive cerebral hemorrhage small and moderate in amount, it may promote the absorption of the intracranial hematoma, and improve the patients′ remote prognosis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA